{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:46:54Z","timestamp":1792799214809,"version":"4.5.0"},"reference-count":64,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"unspecified","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,1,14]]},"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>PRELUCA is a randomised, intervention, non-inferiority study designed to use real-time, longitudinal circulating tumour DNA (ctDNA) measurements to evaluate the efficacy of immunotherapy in patients with advanced non-small cell lung cancer (NSCLC). The primary outcome is overall survival between the two groups: the standard of care group (computer tomography scan evaluation) and intervention group (ctDNA evaluation).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The inclusion and exclusion criteria align with European Society for Medical Oncology treatment guidelines and permit broad inclusion of NSCLC patients, ensuring \u2018real-world\u2019 representativeness. The study uses a tumour-informed method, using baseline next generation sequencing analyses to design patient-specific droplet digital PCR assays, which are run with collected blood samples 1\u2009week prior to the intended treatment, enabling real-time evaluation via ctDNA Response Evaluation Criteria in Solid Tumours.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Inclusion began in July 2023 and patients are now being actively included in five locations across Denmark. Approval by The Committee on Health Research Ethics of Region Zealand was gained on 4 May 2023.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT05889247\">NCT05889247<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-100311","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T16:25:14Z","timestamp":1770049514000},"page":"e100311","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["ctDNA guided immunotherapy in patients with advanced non-small cell lung cancer: a nationwide Danish, randomised, intervention study (PRELUCA\u2014PRediction in LUng CAncer Treatment) \u2013 study protocol"],"prefix":"10.1136","volume":"16","clinical-trial-number":[{"clinical-trial-number":"nct05889247","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05889247","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8520-2200","authenticated-orcid":false,"given":"Michael Elmkvist","family":"Andersen","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology and Palliative Care, Region Zealand, Roskilde, Denmark"},{"name":"University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa Haugaard","family":"Nyhus","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sygehus Lillebalt, Vejle, Region Syddanmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika Maria","family":"Szejniuk","sequence":"additional","affiliation":[{"name":"Department of Oncology & Clinical Cancer Research Center, Aalborg Universitetshospital, Aalborg, North Denmark Region, Denmark"},{"name":"Aalborg University The Faculty of Medicine, Aalborg, North Denmark Region, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stine","family":"Wahlstr\u00f8m","sequence":"additional","affiliation":[{"name":"Department of Oncology and Palliative Medicine, North Zealand Hospital, Copenhagen University Hospital, Copenhagen, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-7784","authenticated-orcid":false,"given":"Signe","family":"Timm","sequence":"additional","affiliation":[{"name":"Oncology, Lillebaelt Hospital - University Hospital of Southern Denmark, Vejle, Denmark"},{"name":"Institute for Regional Health Research, University of Southern Denmark, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Pallisgaard","sequence":"additional","affiliation":[{"name":"Department of Pathology, Zealand University Hospital Roskilde, Roskilde, Region Zealand, Denmark"},{"name":"Roskilde Universitet Institut for Naturvidenskab og Milj\u00f8, Roskilde, Region Zealand, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malene Green","family":"Madsen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Zealand University Hospital Roskilde, Roskilde, Region Zealand, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Dalgaard","family":"Mikkelsen","sequence":"additional","affiliation":[{"name":"Department of Pathology, Zealand University Hospital Roskilde, Roskilde, Region Zealand, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Barlebo","family":"Ahlborn","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine, Rigshospitalet Afdeling for Genetik, Copenhagen, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3829-0210","authenticated-orcid":false,"given":"Julie","family":"Gehl","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Palliative Care, Region Zealand, Roskilde, Denmark"},{"name":"University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malene St\u00f8chkel","family":"Frank","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Palliative Care, Region Zealand, Roskilde, Denmark"},{"name":"University of Copenhagen Faculty of Health and Medical Sciences, Copenhagen, Capital Region of Denmark, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"2026062610401598000_16.2.e100311.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2026062610401598000_16.2.e100311.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"2026062610401598000_16.2.e100311.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.10.017"},{"key":"2026062610401598000_16.2.e100311.4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.800547","article-title":"Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper","volume":"11","author":"Fournier","year":"2021","journal-title":"Front Oncol"},{"key":"2026062610401598000_16.2.e100311.5","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2020200443"},{"key":"2026062610401598000_16.2.e100311.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.6870"},{"key":"2026062610401598000_16.2.e100311.7","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/oncolo\/oyad335","article-title":"Incidence, Correlates, and Prognostic Significance of Mixed Response in Advanced Non-small Cell Lung Cancer","volume":"29","author":"Gerber","year":"2024","journal-title":"Oncologist"},{"key":"2026062610401598000_16.2.e100311.8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/OP.21.00776","article-title":"Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy","volume":"18","author":"Schneider","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"2026062610401598000_16.2.e100311.9","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jgo.2019.08.001","article-title":"Modifiable factors affecting older patients\u2019 quality of life and physical function during cancer treatment","volume":"10","author":"Kirkhus","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"2026062610401598000_16.2.e100311.10","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181622c17"},{"key":"2026062610401598000_16.2.e100311.11","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2767-9764.CRC-22-0258","article-title":"Circulating Tumor DNA Monitoring Reveals Molecular Progression before Radiologic Progression in a Real-life Cohort of Patients with Advanced Non-small Cell Lung Cancer","volume":"2","author":"Frank","year":"2022","journal-title":"Cancer Res Commun"},{"key":"2026062610401598000_16.2.e100311.12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001504","article-title":"Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)","volume":"9","author":"Ricciuti","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026062610401598000_16.2.e100311.13","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1424675","article-title":"Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer","volume":"7","author":"Giroux Leprieur","year":"2018","journal-title":"Oncoimmunology"},{"key":"2026062610401598000_16.2.e100311.14","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-014-0042-0","article-title":"Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade","volume":"2","author":"Lipson","year":"2014","journal-title":"J Immunother Cancer"},{"key":"2026062610401598000_16.2.e100311.15","doi-asserted-by":"publisher","DOI":"10.21873\/cgp.20319"},{"key":"2026062610401598000_16.2.e100311.16","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.215"},{"key":"2026062610401598000_16.2.e100311.17","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.671874","article-title":"The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","volume":"11","author":"Wang","year":"2021","journal-title":"Front Oncol"},{"key":"2026062610401598000_16.2.e100311.18","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy275"},{"key":"2026062610401598000_16.2.e100311.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1917346"},{"key":"2026062610401598000_16.2.e100311.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2026062610401598000_16.2.e100311.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"2026062610401598000_16.2.e100311.22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41416-024-02895-1","article-title":"Real-world evidence for pembrolizumab in non-small cell lung cancer: a nationwide cohort study","volume":"132","author":"Hektoen","year":"2025","journal-title":"Br J Cancer"},{"key":"2026062610401598000_16.2.e100311.23","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/cncr.33984","article-title":"Long-term outcomes in patients with advanced and\/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU20-11)","volume":"128","author":"Kim","year":"2022","journal-title":"Cancer"},{"key":"2026062610401598000_16.2.e100311.24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40880-019-0423-3","article-title":"Long-lasting responses after discontinuation of nivolumab treatment for reasons other than tumor progression in patients with previously treated, advanced non-small cell lung cancer","volume":"39","author":"Kimura","year":"2019","journal-title":"Cancer Commun"},{"key":"2026062610401598000_16.2.e100311.25","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4819-2","article-title":"Efficacy of anti-PD-1\/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316)","volume":"18","author":"Tachihara","year":"2018","journal-title":"BMC Cancer"},{"key":"2026062610401598000_16.2.e100311.26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149"},{"key":"2026062610401598000_16.2.e100311.27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cllc.2023.11.012","article-title":"Clinical and Genomic Characterization of Long-Term Responders Receiving Immune Checkpoint Blockade for Metastatic Non-Small-Cell Lung Cancer","volume":"25","author":"Ghanem","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"2026062610401598000_16.2.e100311.28","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz449.031","article-title":"The characteristics of long-lasting responders to PD-1 inhibitor in advanced non-small cell lung cancer patients","volume":"30","author":"Jo","year":"2019","journal-title":"Ann Oncol"},{"key":"2026062610401598000_16.2.e100311.29","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/s41591-023-02226-6","article-title":"A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer","volume":"29","author":"Assaf","year":"2023","journal-title":"Nat Med"},{"key":"2026062610401598000_16.2.e100311.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.001"},{"key":"2026062610401598000_16.2.e100311.31","unstructured":"Mortensen L , Zitnjak D , Andersen R . Pallierende onkologisk behandling af ikke-sm\u00e5cellet lungekr\u00e6ft uden onkogen drivermutation. DMCGDk; 2024. Available: https:\/\/www.dmcg.dk\/kliniske-retningslinjer\/kliniske-retningslinjer-opdelt-paa-dmcg\/lungecancer\/pallierende-onkologisk-behandling-af-ikke-smacellet-lungekraft-uden-onkogen-drivermutation\/ [Accessed 9 Dec 2025]."},{"key":"2026062610401598000_16.2.e100311.32","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231171580","article-title":"Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors \u2013 can we RECIST? Focus on colorectal cancer","volume":"15","author":"Spindler","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"2026062610401598000_16.2.e100311.33","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1473327","article-title":"Genomic profiling of NSCLC tumors with the TruSight oncology 500 assay provides broad coverage of clinically actionable genomic alterations and detection of known and novel associations between genomic alterations, TMB, and PD-L1","volume":"14","author":"Wallen","year":"2024","journal-title":"Front Oncol"},{"key":"2026062610401598000_16.2.e100311.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2015.04.015"},{"key":"2026062610401598000_16.2.e100311.35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102451","article-title":"The Clinical Value of Measuring Circulating HPV DNA during Chemo-Radiotherapy in Squamous Cell Carcinoma of the Anus","volume":"13","author":"Lef\u00e8vre","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026062610401598000_16.2.e100311.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.013"},{"key":"2026062610401598000_16.2.e100311.37","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02746"},{"key":"2026062610401598000_16.2.e100311.38","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.440"},{"key":"2026062610401598000_16.2.e100311.39","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1039\/C8LC01399C","article-title":"An ultrasensitive test for profiling circulating tumor DNA using integrated comprehensive droplet digital detection","volume":"19","author":"Ou","year":"2019","journal-title":"Lab Chip"},{"key":"2026062610401598000_16.2.e100311.40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.3065"},{"key":"2026062610401598000_16.2.e100311.41","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-23-3321","article-title":"Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation","volume":"30","author":"Rolfo","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026062610401598000_16.2.e100311.42","first-page":"165","article-title":"The Effect of Mutations Determined by Liquid Biopsy on the Progress of the Disease in Advanced Lung Adenocancer","volume":"45","author":"Ergin","year":"2022","journal-title":"Erciyes Med J"},{"key":"2026062610401598000_16.2.e100311.43","doi-asserted-by":"crossref","first-page":"971","DOI":"10.21037\/tlcr-22-818","article-title":"Blood tumor mutational burden and dynamic changes in circulating tumor DNA predict response to pembrolizumab treatment in advanced non-small cell lung cancer","volume":"12","author":"Stensgaard","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"2026062610401598000_16.2.e100311.44","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.2011"},{"key":"2026062610401598000_16.2.e100311.45","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3519"},{"key":"2026062610401598000_16.2.e100311.46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00054","article-title":"Circulating Tumor DNA in Non-Small-Cell Lung Cancer: A Primer for the Clinician","volume":"1","author":"Singh","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2026062610401598000_16.2.e100311.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.03.018"},{"key":"2026062610401598000_16.2.e100311.48","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14071813","article-title":"Genetic Clonality as the Hallmark Driving Evolution of Non-Small Cell Lung Cancer","volume":"14","author":"Nico\u015b","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026062610401598000_16.2.e100311.49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa1408","article-title":"Clonal status of actionable driver events and the timing of mutational processes in cancer evolution","volume":"7","author":"McGranahan","year":"2015","journal-title":"Sci Transl Med"},{"key":"2026062610401598000_16.2.e100311.50","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-020-02175-0","article-title":"Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity","volume":"21","author":"Lee","year":"2020","journal-title":"Genome Biol"},{"key":"2026062610401598000_16.2.e100311.51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00580"},{"key":"2026062610401598000_16.2.e100311.52","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000527","article-title":"Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression","volume":"8","author":"Giroux Leprieur","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026062610401598000_16.2.e100311.53","doi-asserted-by":"crossref","unstructured":"Zhou S , Yang H . Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies. Front Immunol 2023;14. doi:10.3389\/fimmu.2023.1129465","DOI":"10.3389\/fimmu.2023.1129465"},{"key":"2026062610401598000_16.2.e100311.54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.12003"},{"key":"2026062610401598000_16.2.e100311.55","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00289","article-title":"Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase\/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors","volume":"8","author":"Hu","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"2026062610401598000_16.2.e100311.56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0143"},{"key":"2026062610401598000_16.2.e100311.57","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1408617"},{"key":"2026062610401598000_16.2.e100311.58","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12484","article-title":"Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults","volume":"7","author":"Young","year":"2016","journal-title":"Nat Commun"},{"key":"2026062610401598000_16.2.e100311.59","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006284","article-title":"Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA","volume":"11","author":"Semenkovich","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026062610401598000_16.2.e100311.60","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jmoldx.2018.07.005","article-title":"Effects of Collection and Processing Procedures on Plasma Circulating Cell-Free DNA from Cancer Patients","volume":"20","author":"Risberg","year":"2018","journal-title":"J Mol Diagn"},{"key":"2026062610401598000_16.2.e100311.61","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2016.03.012"},{"key":"2026062610401598000_16.2.e100311.62","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0386"},{"key":"2026062610401598000_16.2.e100311.63","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0047"},{"key":"2026062610401598000_16.2.e100311.64","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1200\/PO.20.00321","article-title":"Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy","volume":"5","author":"Thompson","year":"2021","journal-title":"JCO Precis Oncol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-100311","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:40:42Z","timestamp":1782495642000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-100311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":64,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,2]]},"published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1136\/bmjopen-2025-100311"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-100311","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]}}}